Sanofi and Orano Partner to advance next-gen radioligand medicines

Sanofi and Orano Med, which is a part of the Orano Group and specializes in targeted alphatherapies for cancer treatment, have agreed to collaborate in order to advance the development of advanced radioligand treatments for rare cancers.

Sanofi and Orano will collaborate with Orano Med to create a new entity dedicated to developing next-generation radioligand therapies using lead-212 alpha-emitting isotopes, utilizing their expertise and radioligand pipeline. This deal comes after Sanofi's announcement of a sole licensing agreement with Orano Med and RadioMedix to progress radioligand therapies (RLTs) in rare cancers, specifically targeting the late-stage project, AlphaMedix.

Paul Hudson, CEO, Sanofi, said: “We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive groundbreaking progress in the fight against cancer. As a French biopharmaceutical company, we are deeply committed to fostering and enabling innovation in our home country. This collaboration is part of a broader effort to strengthen our ties within the scientific community, both in France and globally, with the goal of advancing the development of cutting-edge treatments for patients.”

Nicolas Maes, CEO, Orano Group, said: “The success of Orano Med is an example of our group's ability to diversify beyond our core nuclear business. By applying our expertise in nuclear materials to fields like targeted alpha therapies, we are demonstrating that nuclear technology can have a positive societal impact, not just for energy and climate, but also for human health. This innovation reflects Orano's commitment to exploring new opportunities and taking bold steps to address some of the world’s most pressing challenges."